|
Abbreviation
|
Formula
|
Mass
|
Main Class
|
Sub Class
|
|
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C88H158N2O37
|
1835.054355
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C88H160N2O37
|
1837.070005
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C86H155N3O38
|
1838.028869
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Fucα2-3(Galβ1-4)GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C88H157N3O37
|
1848.049604
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Fucα2-3GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C88H157N3O37
|
1848.049604
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C88H157N3O37
|
1848.049604
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Fucα2-3Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C88H157N3O37
|
1848.049604
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Fucα2-3(Galβ1-4)GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C88H159N3O37
|
1850.065254
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Fucα2-3GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C88H159N3O37
|
1850.065254
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C88H159N3O37
|
1850.065254
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Fucα2-3Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C88H159N3O37
|
1850.065254
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C86H154N4O38
|
1851.024118
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C88H158N2O38
|
1851.049270
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C88H160N2O38
|
1853.064920
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C84H151NO43
|
1861.965997
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C88H157N3O38
|
1864.044519
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C88H159N3O38
|
1866.060169
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C84H150N2O43
|
1874.961245
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Fucα2-3(Galβ1-4)GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C90H161N3O37
|
1876.080904
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Fucα2-3GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C90H161N3O37
|
1876.080904
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C90H161N3O37
|
1876.080904
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Fucα2-3Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C90H161N3O37
|
1876.080904
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Fucα2-3(Galβ1-4)GlcNAcβ1-6GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C90H163N3O37
|
1878.096554
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Fucα2-3GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C90H163N3O37
|
1878.096554
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C90H163N3O37
|
1878.096554
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3(Fucα2-3Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C90H163N3O37
|
1878.096554
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C88H158N4O38
|
1879.055418
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C86H155NO43
|
1889.997297
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C90H161N3O38
|
1892.075819
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C90H163N3O38
|
1894.091469
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-3)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C86H153N3O42
|
1899.992879
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C86H154N2O43
|
1902.992545
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C90H160N4O38
|
1905.071068
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C90H162N4O38
|
1907.086718
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C88H159NO43
|
1918.028597
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-3)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C88H157N3O42
|
1928.024179
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C88H158N2O43
|
1931.023845
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C92H164N4O38
|
1933.102368
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C92H166N4O38
|
1935.118018
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Fucα1-2Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 34:1;O2
|
C88H156N4O42
|
1941.019428
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C90H161NO43
|
1944.044247
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C90H163NO43
|
1946.059897
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-3)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 38:1;O2
|
C90H161N3O42
|
1956.055479
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C90H162N2O43
|
1959.055146
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcα1-3GalNAcβ1-3(Fucα1-2Galβ1-3GalNAcβ1-4)Galα1-4Galβ1-4Glcβ-Cer 36:1;O2
|
C90H160N4O42
|
1969.050728
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 44:2;O2
|
C92H165NO43
|
1972.075547
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galα1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 44:1;O2
|
C92H167NO43
|
1974.091197
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-3)GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 40:1;O2
|
C92H165N3O42
|
1984.086779
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 42:2;O2
|
C92H164N2O43
|
1985.070796
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
|
GalNAcβ1-3Galα1-3Galα1-3Galα1-3Galα1-3Galα1-4Galβ1-4Glcβ-Cer 42:1;O2
|
C92H166N2O43
|
1987.086446
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|